Humana
HUM
$414.85
-0.57%
Humana Inc. is one of the largest private health insurers in the United States, operating a business built almost entirely around government-sponsored programs — Medicare Advantage, Medicaid, and the military's Tricare program — supplemented by its CenterWell care delivery platform spanning primary care, home health, and pharmacy benefit management. The company is a pure-play Medicare Advantage specialist rather than a diversified managed-care conglomerate, which makes it structurally more sensitive to CMS rate-setting and risk-coding dynamics than peers such as UnitedHealth or CVS. The current investor narrative is a high-stakes turnaround: after a deeply loss-making 2025 (a Q4 net loss of $796 million and negative $6.61 diluted EPS), Humana has swung back to profitability in 2026, with Q1 EPS of $9.85 and Q2 EPS of $5.79, while revenue growth reaccelerated to 26.2% year over year. The debate centers on whether margin recovery is durable — the April 2026 CMS decision to boost 2027 Medicare Advantage payment rates materially improved revenue visibility and sentiment, and the stock has re-rated sharply, but negative earnings revisions and expected losses flagged in recent coverage suggest the market is still testing the credibility of the recovery.…
HUM
Humana
$414.85
Related headlines
Investment Opinion: Should I buy HUM Today?
Rating: Hold. The core thesis is that Humana is a credible but unproven margin-recovery story — the CMS 2027 rate boost and swing to Q1 2026 EPS of $9.85 have driven a 96% six-month rally, but negative $443 million trailing FCF and a forward PE of 24.7x mean the easy money has likely been made. The analyst consensus of 'buy' (mean 1.96) with an average target of $465.13 implies only +10.2% upside, a modest reward relative to the risk.
Supporting evidence is mixed but leans cautiously constructive: revenue is growing 26.2% YoY, profitability has inflected from a -$6.61 Q4 2025 EPS to $5.79 in Q2 2026, and the PS ratio of 0.24x and EV/Sales of 0.29x are deep-value multiples versus Humana's own historical band of 2.12x in Q4 2023. However, the forward PE of 24.7x is a premium to peers, trailing FCF is negative, and the current ratio of 0.72 is a genuine liquidity concern. The 13.6x EV/EBITDA sits at a discount to a fully recovered franchise but reflects real margin fragility.
Key risks that could invalidate the thesis are renewed medical cost inflation (already hinted by the Q1-to-Q2 gross margin drop from 14.98% to 13.45%), continued negative free cash flow forcing balance-sheet strain, and a wide analyst dispersion ($280-$596) that keeps volatility elevated. This Hold would upgrade to Buy if gross margins stabilize above 14% and FCF turns positive, or downgrade to Sell if Q3 2026 EPS falls below the $5.79 Q2 level or margins compress further. Verdict: fairly valued to modestly overvalued after the rally — the stock is cheap on sales but fully priced on forward earnings relative to peers.
Sign up to view all
HUM 12-Month Price Forecast
Humana presents a validated-but-crowded turnaround: the 96.1% six-month rally, CMS 2027 rate boost, and swing to profitability are real, but the forward PE of 24.7x and negative FCF mean the risk/reward is now balanced rather than compelling. The sequential margin compression from Q1 to Q2 (14.98% to 13.45%) is the pivotal variable — if it stabilizes, the base case of $440-$490 is achievable, but if it deteriorates, the $280-$350 bear case becomes live. Analyst sentiment is constructive but dispersed ($280-$596 range), and the modest +10.2% upside to the average target caps near-term reward. I would upgrade to bullish on a confirmed FCF inflection and gross margin above 14%, and downgrade to bearish if Q3 2026 EPS misses the $5.79 Q2 level.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Humana's 12-month outlook, with a consensus price target around $465.13 and implied upside of +12.1% versus the current price.
Average Target
$465.13
0 analysts
Implied Upside
+12.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$280 - $596
Analyst target range
Coverage is broad and constructive: 24 analysts cover Humana with a consensus recommendation of "buy" (mean rating 1.96 on a 1-to-5 scale where 1 is strong buy), and the average target price of $465.13 implies roughly +10.2% upside from the current $422.07. The consensus leans bullish but not aggressively so — the mean rating just below 2.0 reflects a mix of outright buys and neutral holds, consistent with the institutional ratings flow showing Barclays upgrading to Overweight in late September 2026 while JP Morgan, UBS, and TD Cowen remain Neutral/Hold and Raymond James downgraded to Market Perform in July.
The target range is exceptionally wide — from a low of $280.00 to a high of $596.00, a spread of more than 2x — which signals genuine disagreement about the durability of the margin recovery rather than a lack of coverage. The high target of $596 assumes full multiple expansion and sustained membership growth with medical cost trends under control, while the low target of $280 prices in margin compression and a return to the loss-making dynamics of 2025. Consensus forward EPS of $35.53 (range $33.49–$37.33) on estimated revenue of $204.6 billion implies the Street expects a dramatic earnings rebound from the trailing $0.04, and the recent upgrade/downgrade pattern — one upgrade, one downgrade, and several reiterations — suggests analysts are repositioning rather than converging, keeping volatility elevated around earnings and CMS announcements.
Bulls vs Bears: HUM Investment Factors
The bull case rests on a genuine, policy-assisted turnaround: the CMS 2027 rate boost, 26.2% revenue growth, and a swing from -$6.61 EPS in Q4 2025 to $9.85 in Q1 2026 have driven a 96% six-month rally with strong relative strength. The bear case is equally concrete: negative $443 million trailing FCF, a current ratio of 0.72, sequential margin compression from Q1 to Q2, and a forward PE of 24.7x that already discounts much of the recovery. On balance, the bear evidence on cash flow and margin durability is currently the more verifiable risk, while the bull case leans heavily on a single policy catalyst and forward estimates that have not yet been proven. The single most important tension is whether the Q1-to-Q2 gross margin decline (14.98% to 13.45%) is a one-off seasonal blip or the start of renewed medical cost inflation — how that resolves will determine whether the 96% rally is a durable trend reversal or an overshoot.
Bullish
- Powerful momentum with massive relative strength: HUM is up 96.1% over six months and 59.6% YTD versus SPY's 6.45% and 11.45%, a relative strength spread of +89.7 and +48.1 points respectively. The October 9 gap from $387.12 to $431.87 on elevated volume has held, with the stock at $422.07 and up 12.6% in the past month.
- CMS 2027 rate boost improves revenue visibility: The April 2026 CMS decision to raise 2027 Medicare Advantage payment rates was larger than expected and directly de-risks Humana's core revenue base, since nearly all membership stems from government programs. This single policy event is the primary driver behind the sharp re-rating and the analyst consensus 'buy' rating (mean 1.96).
- Revenue reaccelerating at 26.2% YoY: Q2 2026 revenue of $40.87 billion grew 26.2% from $32.39 billion a year earlier, with Q1 2026 also up sharply to $39.65 billion from $32.11 billion. This growth trajectory is well above what a mature insurer typically sustains and implies membership gains plus premium rate increases are flowing through.
- Profitability inflected from deep losses: After a Q4 2025 net loss of $796 million (-$6.61 EPS), Humana posted Q1 2026 EPS of $9.85 and Q2 2026 EPS of $5.79, with Q2 net income of $693 million. Consensus forward EPS of $35.53 versus trailing EPS of $0.04 implies the Street expects a dramatic earnings rebound.
Bearish
- Negative free cash flow is a red flag: Trailing free cash flow is -$443 million, with Q2 2026 operating cash flow of -$426 million and FCF of -$558 million. The 1.39% dividend (36.2% payout ratio) is being funded by balance-sheet capacity rather than organic cash generation, a genuine risk if margin recovery stalls.
- Sequential margin compression Q1 to Q2: Gross margin fell from 14.98% in Q1 2026 to 13.45% in Q2, and operating margin dropped from 3.98% to 3.33%, while net income fell from $1.19 billion to $693 million. This suggests medical cost trends may be re-accelerating, and the trailing net margin of just 0.92% leaves almost no cushion for a medical loss ratio miss.
- Tight liquidity and leverage: The current ratio of just 0.72 indicates weak near-term liquidity, and debt-to-equity of 0.73 is meaningful for a low-margin insurer. Q1 2026 saw $1.67 billion of debt repayment alongside $911 million of acquisitions, straining the balance sheet while FCF is negative.
- Valuation offers little downside protection: The forward PE of 24.7x is not cheap versus large-cap managed-care peers trading in the mid-to-high teens, and the trailing PE of 25.95x sits mid-range of its own 12x-40x historical band. The stock has already re-rated 96% in six months, so much of the recovery is priced in.
HUM Technical Analysis
Humana is in a powerful, sustained uptrend that has carried the stock 44.9% higher over the past year and 59.6% year to date, dramatically outperforming the S&P 500's 13.1% and 11.5% respective gains. At $422.07, the stock sits at roughly 89% of its 52-week range (low of $163.11, high of $456.50), positioning it near the top of its annual band — a zone that historically signals either momentum leadership or overextension, and the fact that the stock is still 7.5% below its 52-week high despite the strong run suggests it is consolidating rather than blowing off. The 45.1% maximum drawdown recorded over the trailing period underscores that this is a high-recovery, high-volatility name rather than a smooth compounder.
Short-term momentum is accelerating and confirming the longer-term trend rather than diverging from it: the stock is up 12.6% over the past month and 8.4% over three months, with the one-month gain far outpacing the three-month gain, indicating a fresh leg higher. The 96.1% six-month gain is the standout figure, reflecting a violent re-rating off the 2025 lows, and the relative strength versus SPY is positive across every window — +13.6 points over one month, +5.6 over three months, and a remarkable +89.7 over six months. The October 9 gap from $387.12 to $431.87 on elevated volume is the key momentum event, and the stock has held most of that move, closing at $422.07 with a modest +0.26% daily gain on roughly 1.2 million shares.
Key technical support sits at the 52-week low of $163.11, with a more actionable intermediate floor in the $380–$390 zone where the stock consolidated through August and September; resistance is the 52-week high of $456.50, and a breakout above that level would confirm the recovery as a full trend reversal with blue-sky upside. A breakdown below $380 would signal the October gap is failing and refocus attention on the $350 area. With a beta of just 0.744, Humana is roughly 26% less volatile than the market on a statistical basis — unusual for a stock that has moved 96% in six months — meaning the realized volatility is event-driven (CMS rate decisions, earnings) rather than market-correlated, which argues for position sizing based on catalyst risk rather than index beta.
Beta
0.74
0.74x market volatility
Max Drawdown
-45.1%
Largest decline past year
52-Week Range
$163-$457
Price range past year
Annual Return
+41.9%
Cumulative gain past year
| Period | HUM Return | S&P 500 |
|---|---|---|
| 1m | +4.3% | -0.2% |
| 3m | +13.5% | +5.5% |
| 6m | +75.5% | +7.1% |
| 1y | +41.9% | +12.3% |
| ytd | +56.9% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HUM Fundamental Analysis
Revenue is growing at a robust clip: Q2 2026 revenue of $40.87 billion represents 26.2% year-over-year growth versus $32.39 billion in Q2 2025, and the multi-quarter trend shows acceleration — Q1 2026 revenue of $39.65 billion grew from $32.11 billion a year earlier, while Q4 2025's $32.52 billion was up from $29.21 billion. The Insurance segment dominates at $39.14 billion, with CenterWell contributing $6.79 billion and $5.06 billion in eliminations, meaning the core Medicare book is driving essentially all of the growth. This trajectory implies the investment case rests on membership gains and premium rate increases flowing through, but the 26% growth rate is well above what a mature insurer typically sustains, raising the question of how much is rate versus volume.
Profitability has inflected decisively but remains thin: Q2 2026 net income was $693 million on a 1.70% net margin and 13.45% gross margin, a sharp improvement from the Q4 2025 loss of $796 million (-2.45% net margin) but a step down from Q1 2026's $1.19 billion and 2.99% net margin. The sequential margin compression from Q1 to Q2 (gross margin 14.98% to 13.45%, operating margin 3.98% to 3.33%) is the key watch item — it suggests medical cost trends may be re-accelerating, and the trailing net margin of just 0.92% versus a 1.12% operating margin leaves almost no cushion. For a Medicare Advantage insurer, sub-2% net margins are structurally normal but leave earnings highly levered to any medical loss ratio miss.
Balance sheet and cash flow are the weak link: trailing free cash flow is negative $443 million, Q2 2026 operating cash flow was -$426 million with FCF of -$558 million, and the company carries a debt-to-equity ratio of 0.73 with a current ratio of just 0.72, indicating tight near-term liquidity. ROE of 6.7% and ROA of 3.9% are modest, and the negative FCF means growth is being funded partly through the balance sheet — Q1 2026 saw $1.67 billion of debt repayment alongside $911 million of acquisitions. The company does pay a dividend (1.39% yield, 36.2% payout ratio), but with FCF negative, the dividend is being covered by balance-sheet capacity rather than organic cash generation, which is a genuine financial risk if the margin recovery stalls.
Quarterly Revenue
$40.9B
2026-06
Revenue YoY Growth
+26.2%
YoY Comparison
Gross Margin
13.5%
Latest Quarter
Free Cash Flow
$-443000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HUM Overvalued?
Because Humana is profitable on a trailing basis (net income positive, EPS of $0.04 on a trailing basis per the key metrics, though quarterly EPS is far higher), the PE ratio is the appropriate primary metric, and the trailing PE of 25.95x versus a forward PE of 24.70x implies the market expects only modest earnings growth — a surprisingly narrow gap given the consensus forward EPS estimate of $35.53. The trailing EPS figure of $0.04 appears distorted by the 2025 loss quarters rolling through the TTM calculation, making the forward PE of 24.7x the more meaningful anchor; the PS ratio of 0.24x and EV/Sales of 0.29x are extremely low in absolute terms, reflecting the low-margin insurance model.
Against the Medical-Healthcare Plans industry, Humana's 0.24x PS and 0.29x EV/Sales are deep-value multiples, and its 13.6x EV/EBITDA sits at a discount to what a recovering managed-care franchise would typically command, while the 1.75x P/B is modest for a company with a 6.7% ROE. The premium/discount picture is mixed: the forward PE of 24.7x is not cheap versus a sector where large-cap peers trade in the mid-to-high teens, but the sub-0.3x sales multiples suggest the market is pricing in margin fragility rather than growth. The negative PEG ratio of -18.55 is a mechanical artifact of the loss-making base period and should be disregarded.
Historically, Humana's own valuation band has compressed dramatically: the PS ratio was 2.12x in Q4 2023 and 2.87x in Q4 2022, versus 0.24x today, while the PE ratio ranged from 12x to 40x across 2023–2025 and now sits at 25.95x trailing. The stock is near the low end of its own historical sales multiple band but mid-range on earnings, which is the classic signature of a margin-recovery story — the market has repriced the equity (up 96% in six months) without yet restoring the revenue multiple, implying investors are paying for earnings normalization rather than top-line optimism. If margins hold, the historical PS range suggests meaningful re-rating potential; if they roll over, the current multiple offers little downside protection.
PE
26.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 6x~21x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated and quantifiable. Trailing free cash flow is -$443 million, Q2 2026 operating cash flow was -$426 million, and the current ratio of 0.72 signals tight near-term liquidity, meaning the 1.39% dividend (36.2% payout) is being covered by balance-sheet capacity rather than cash generation. Margins are razor-thin — trailing net margin of 0.92% and operating margin of 1.12% — so a modest medical loss ratio miss could erase earnings entirely, as demonstrated by the Q4 2025 net loss of $796 million. Revenue is also highly concentrated: the Insurance segment at $39.14 billion dominates total revenue, leaving Humana structurally exposed to CMS rate-setting and risk-coding dynamics with no diversified buffer like UnitedHealth or CVS.
Market and competitive risks center on valuation compression and sector divergence. The forward PE of 24.7x is a premium to large-cap managed-care peers in the mid-to-high teens, and the stock has already rallied 96.1% in six months, so much of the recovery is priced in; any disappointment risks a sharp de-rating. Recent news highlights a growing divergence in managed care, with UnitedHealth beating Q3 estimates while Humana's struggles are noted, and coverage explicitly flags negative earnings revisions and expected losses despite the 11.6% October jump. Beta of 0.744 means market-wide selloffs are less of a threat than event risk — CMS announcements and earnings — but the 45.1% maximum drawdown shows how violently this name can move when catalysts turn adverse.
The worst-case scenario is a renewed medical cost acceleration that compresses the already-thin 0.92% net margin, forcing another loss-making quarter and a credibility hit to the turnaround narrative. In that chain of events, the stock would likely retest the $380-$390 gap-fill zone and then the $350 area, with the analyst low target of $280 representing a -33.7% downside from $422.07. A full reversion toward the 52-week low of $163.11 would imply a catastrophic -61.4% loss, though that would require a policy shock on top of margin deterioration. A realistic adverse case is a decline of roughly -25% to -34%, to the $280-$315 range, if Q3 or Q4 2026 earnings show margins rolling over.
FAQ
Ranked by severity: first, financial/liquidity risk — trailing FCF of -$443 million, a current ratio of 0.72, and a 1.39% dividend funded by balance-sheet capacity rather than cash generation. Second, margin/medical cost risk — the Q1-to-Q2 gross margin drop from 14.98% to 13.45% and a 0.92% trailing net margin leave almost no cushion for a medical loss ratio miss. Third, concentration/regulatory risk — nearly all membership stems from Medicare, Medicaid, and Tricare, making Humana structurally exposed to CMS rate-setting and risk-coding rules. Fourth, valuation/competitive risk — the forward PE of 24.7x is a premium to peers, and recent news highlights divergence with UnitedHealth, which beat Q3 estimates while Humana's struggles were noted.
The 12-month forecast has three scenarios: a base case (50% probability) of $440-$490, aligned with the analyst average target of $465.13 and consensus forward EPS of $35.53; a bull case (25%) of $520-$596, aligned with the analyst high target and assuming full margin recovery and multiple expansion; and a bear case (25%) of $280-$350, aligned with the analyst low target and assuming medical cost re-acceleration. The base case is most likely, resting on the key assumption that gross margins hold in the 13.5%-15% range and the CMS 2027 rate boost flows through as expected. The exceptionally wide $280-$596 target spread reflects genuine disagreement on margin durability.
The valuation picture is genuinely mixed. On sales, HUM is deeply cheap at 0.24x PS and 0.29x EV/Sales versus its own historical band of 2.12x in Q4 2023 and 2.87x in Q4 2022, and its 13.6x EV/EBITDA is a discount to a fully recovered franchise. On earnings, however, the forward PE of 24.7x is a premium to large-cap managed-care peers in the mid-to-high teens, and the trailing PE of 25.95x sits mid-range of its 12x-40x history. The market is paying for earnings normalization rather than top-line optimism — it has repriced the equity 96% without restoring the revenue multiple. This implies the market expects margins to hold; if they roll over, the current multiple offers little downside protection.
From a risk/reward perspective, HUM is a balanced-to-cautious buy at best after its 96.1% six-month rally. The average analyst target of $465.13 implies only +10.2% upside, while the bear-case low target of $280 represents -33.7% downside, so the reward-to-risk is roughly 1:3 against you at current levels. The positives are real — 26.2% revenue growth, a swing to $9.85 Q1 EPS, and the CMS 2027 rate boost — but negative $443 million trailing FCF and a 0.72 current ratio mean the margin recovery must be proven. It is a reasonable buy for risk-tolerant investors on pullbacks toward the $380-$390 support zone, but chasing at $422 offers thin margin of safety.
HUM is better suited to a medium-to-long-term holding period of at least 12-18 months rather than short-term trading, despite its event-driven volatility. The turnaround thesis — margin normalization, CMS rate tailwinds, and FCF inflection — needs multiple quarters to prove out, and the 0.744 beta means market-wide moves are less relevant than earnings and CMS catalysts. The 1.39% dividend yield is modest and currently unfunded by FCF, so income is not the draw. Short-term traders could exploit the $380-$390 support and $456.50 resistance range, but the 45.1% maximum drawdown and 2x analyst target dispersion mean position sizing should be based on catalyst risk, not index beta.